Our Technology

We have successfully developed a state-of-the-art mRNA-display-based peptide screening platform in-house, designed for exceptional efficiency and robustness. This platform enables us to rapidly identify and optimize novel peptide hits using customized libraries carefully tailored to target a wide range of applications. Additionally, our proprietary cyclization strategies facilitate the creation of cyclic peptides, which provide significant advantages, including greater stability, improved binding affinity, and enhanced specificity over their linear counterparts. By seamlessly integrating mRNA-display technology with our innovative approaches, we are poised to accelerate the discovery of novel therapeutic peptides while maximizing their pharmacological potential.